Metabolic Bariatric Surgery in the Era of GLP-1 Receptor Agonists for Obesity Management
2024

Bariatric Surgery and GLP-1 Medications for Obesity

Sample size: 83346 publication Evidence: moderate

Author Information

Author(s): Kevin Lin, Ateev Mehrotra, Thomas C. Tsai

Primary Institution: Harvard Medical School

Hypothesis

How does the increase in GLP-1 receptor agonist prescriptions affect the rates of metabolic bariatric surgery among adults without diabetes?

Conclusion

The study found a significant increase in GLP-1 RA prescriptions and a decrease in metabolic bariatric surgery rates among adults without diabetes from 2022 to 2023.

Supporting Evidence

  • GLP-1 RA prescriptions increased by 105.6% from 2022 to 2023.
  • Metabolic bariatric surgery rates decreased by 8.7% during the same period.
  • Patients undergoing metabolic bariatric surgery were more medically complex than those prescribed GLP-1 RAs.

Takeaway

This study shows that more people are getting weight loss medications instead of surgery, which is a big change in how obesity is treated.

Methodology

A cross-sectional study using claims data from 16.8 million unique deidentified adult patients without diabetes.

Potential Biases

Potential confounding from variations in patient adherence to GLP-1 RAs.

Limitations

The study's cross-sectional nature and potential confounding factors such as patient adherence to GLP-1 RAs.

Participant Demographics

Adults without diabetes, with a focus on those prescribed GLP-1 RAs and those undergoing metabolic bariatric surgery.

Statistical Information

P-Value

<.001

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1001/jamanetworkopen.2024.41380

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication